Jardiance Drives Boehringer Ingelheim Through First Half, Market Volatility Expected To Continue
Total Pharma Sales Up By 4.4%
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.
You may also be interested in...
Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) reduces cardiovascular deaths and hospitalizations in certain heart failure patients regardless of whether they have diabetes, and regulatory submissions are expected for the additional indication later this year.
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.